Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib maintenance in mantle cell lymphoma
NCT06341556Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- May 2024
- Primary completion
- Mar 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in mantle cell lymphoma (MCL), sponsored by Fudan University. Started May 2024; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06341556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341556.